$599

Dasiglucagon Ph3 Meets Primary and Secondary Endpoints

Zealand Pharma announced positive topline results and held a subsequent investor call to discuss data from its Ph3 pivotal dasiglucagon hypoglycemia rescue trial. Below, FENIX provides an overview of the results and potential impact on the glucagon rescue market.

This content is for Read Less members only.
Register
Already a member? Log in here